Asset profile
BAY3283142
Small molecule
Evidence outlook · results not reported
ALPINE 1 (NCT06522997) · Chronic Kidney Disease
The lead study's design has limits that temper confidence (see the rationale below), and its results have not been reported. This tier describes the design, not an outcome.
ALPINE 1 (NCT06522997): The study used random assignment, quadruple masking, and a placebo control with a large enrollment of 1,222 participants. Its primary endpoint was the surrogate measure of change in UACR, and the primary comparison cannot yet be judged because results are not posted.
Also in development:Hypertension · Phase 1
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
123 competitors in this universe: 3 direct rivals (same mechanism and indication), 2 same-class, 118 same-indication; 93 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| BAY3283142: this drug | Phase 2 | Small molecule | Soluble guanylate cyclase | ||
| Riociguat (Adempas) | Phase 3 | Small molecule | Soluble guanylate cyclase | ||
| Praliciguat | Phase 2 | Small molecule | Soluble guanylate cyclase | ||
| SK-08 | Phase 1 | Small molecule | Soluble guanylate cyclase | ||
| Vericiguat (Verquvo) | Approved | Small molecule | Soluble guanylate cyclase | ||
| Mosliciguat | Phase 3 | Small molecule | Soluble guanylate cyclase | ||
| Aprocitentan (Tryvio) | Approved | Small molecule | Endothelin receptor (ETA/ETB, dual) | ||
| Atrasentan (Vanrafia) | Approved | Small molecule | Endothelin A receptor | ||
| Avacopan (Tavneos) | Approved | Small molecule | Complement C5a receptor 1 (C5aR1/CD88) | ||
| Baxdrostat (Baxfendy) | Approved | Small molecule | Aldosterone synthase (CYP11B2) | ||
| Bosentan (Tracleer) | Approved | Small molecule | Endothelin receptor (ETA/ETB, dual) | ||
| Budesonide (targeted-Release) (TARPEYO / Nefecon) | Approved | Small molecule | Glucocorticoid receptor | ||
| Canagliflozin (Invokana) | Approved | Small molecule | SGLT2 | ||
| Dapagliflozin (Farxiga / Forxiga) | Approved | Small molecule | SGLT2 | ||
| Daprodustat (Jesduvroq) | Approved | Small molecule | HIF prolyl hydroxylase (HIF-PH1/2/3) | ||
| Difelikefalin (Korsuva) | Approved | Peptide | Kappa-opioid receptor (agonist, peripherally restricted) |
…and 108 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.